ResearchSpace

Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice

Show simple item record

dc.contributor.author O'Kennedy, Maretha M
dc.contributor.author Coetzee, P
dc.contributor.author Koekemoer, O
dc.contributor.author Du Plessis, L
dc.contributor.author Lourens, CW
dc.contributor.author Kwezi, Lusisizwe
dc.contributor.author Du Preez, Ilse
dc.contributor.author Mamputha, Sipho
dc.contributor.author Rutkowska, Daria A
dc.contributor.author Lemmer, Yolandy
dc.date.accessioned 2022-12-02T07:40:36Z
dc.date.available 2022-12-02T07:40:36Z
dc.date.issued 2022-08
dc.identifier.citation O'Kennedy, M.M., Coetzee, P., Koekemoer, O., Du Plessis, L., Lourens, C., Kwezi, L., Du Preez, I. & Mamputha, S. et al. 2022. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. <i>Vaccine, 40(35).</i> http://hdl.handle.net/10204/12545 en_ZA
dc.identifier.issn 0264-410X
dc.identifier.issn 1873-2518
dc.identifier.uri https://doi.org/10.1016/j.vaccine.2022.06.079
dc.identifier.uri http://hdl.handle.net/10204/12545
dc.description.abstract Next generation vaccines have the capability to contribute to and revolutionise the veterinary vaccine industry. African horse sickness (AHS) is caused by an arbovirus infection and is characterised by respiratory distress and/or cardiovascular failure and is lethal to horses. Mandatory annual vaccination in endemic areas curtails disease occurrence and severity. However, development of a next generation AHSV vaccine, which is both safe and efficacious, has been an objective globally for years. In this study, both AHSV serotype 5 chimaeric virus-like particles (VLPs) and soluble viral protein 2 (VP2) were successfully produced in Nicotiana benthamiana ΔXT/FT plants, partially purified and validated by gel electrophoresis, transmission electron microscopy and liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing before vaccine formulation. IFNAR-/- mice vaccinated with the adjuvanted VLPs or VP2 antigens in a 10 µg prime-boost regime resulted in high titres of antibodies confirmed by both serum neutralising tests (SNTs) and enzyme-linked immunosorbent assays (ELISA). Although previous studies reported high titres of antibodies in horses when vaccinated with plant-produced AHS homogenous VLPs, this is the first study demonstrating the protective efficacy of both AHSV serotype 5 chimaeric VLPs and soluble AHSV-5 VP2 as vaccine candidates. Complementary to this, coating ELISA plates with the soluble VP2 has the potential to underpin serotype-specific serological assays. en_US
dc.format Abstract en_US
dc.language.iso en en_US
dc.relation.uri https://www.sciencedirect.com/science/article/pii/S0264410X22008489#! en_US
dc.source Vaccine, 40(35) en_US
dc.subject African horse sickness virus en_US
dc.subject AHSV en_US
dc.subject Himaeric virus-like particles en_US
dc.subject Orbivirus en_US
dc.subject Soluble viral protein 2 en_US
dc.subject VLPs en_US
dc.subject VP2 en_US
dc.title Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice en_US
dc.type Article en_US
dc.description.pages 5160-5169 en_US
dc.description.note Copyright: 2022 Elsevier Ltd. All rights reserved. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://doi.org/10.1016/j.vaccine.2022.06.079 en_US
dc.description.cluster Next Generation Health en_US
dc.description.cluster Chemicals en_US
dc.description.impactarea Vetnry Mol Diagnostics and Vac en_US
dc.description.impactarea BT: Technology Demonstration en_US
dc.description.impactarea Human Molecular Diagnostics en_US
dc.identifier.apacitation O'Kennedy, M. M., Coetzee, P., Koekemoer, O., Du Plessis, L., Lourens, C., Kwezi, L., ... Lemmer, Y. (2022). Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. <i>Vaccine, 40(35)</i>, http://hdl.handle.net/10204/12545 en_ZA
dc.identifier.chicagocitation O'Kennedy, Martha M, P Coetzee, O Koekemoer, L Du Plessis, CW Lourens, Lusisizwe Kwezi, Ilse Du Preez, Sipho Mamputha, Daria A Rutkowska, and Yolandy Lemmer "Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice." <i>Vaccine, 40(35)</i> (2022) http://hdl.handle.net/10204/12545 en_ZA
dc.identifier.vancouvercitation O'Kennedy MM, Coetzee P, Koekemoer O, Du Plessis L, Lourens C, Kwezi L, et al. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. Vaccine, 40(35). 2022; http://hdl.handle.net/10204/12545. en_ZA
dc.identifier.ris TY - Article AU - O'Kennedy, Martha M AU - Coetzee, P AU - Koekemoer, O AU - Du Plessis, L AU - Lourens, CW AU - Kwezi, Lusisizwe AU - Du Preez, Ilse AU - Mamputha, Sipho AU - Rutkowska, Daria A AU - Lemmer, Yolandy AB - Next generation vaccines have the capability to contribute to and revolutionise the veterinary vaccine industry. African horse sickness (AHS) is caused by an arbovirus infection and is characterised by respiratory distress and/or cardiovascular failure and is lethal to horses. Mandatory annual vaccination in endemic areas curtails disease occurrence and severity. However, development of a next generation AHSV vaccine, which is both safe and efficacious, has been an objective globally for years. In this study, both AHSV serotype 5 chimaeric virus-like particles (VLPs) and soluble viral protein 2 (VP2) were successfully produced in Nicotiana benthamiana ΔXT/FT plants, partially purified and validated by gel electrophoresis, transmission electron microscopy and liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing before vaccine formulation. IFNAR-/- mice vaccinated with the adjuvanted VLPs or VP2 antigens in a 10 µg prime-boost regime resulted in high titres of antibodies confirmed by both serum neutralising tests (SNTs) and enzyme-linked immunosorbent assays (ELISA). Although previous studies reported high titres of antibodies in horses when vaccinated with plant-produced AHS homogenous VLPs, this is the first study demonstrating the protective efficacy of both AHSV serotype 5 chimaeric VLPs and soluble AHSV-5 VP2 as vaccine candidates. Complementary to this, coating ELISA plates with the soluble VP2 has the potential to underpin serotype-specific serological assays. DA - 2022-08 DB - ResearchSpace DP - CSIR J1 - Vaccine, 40(35) KW - African horse sickness virus KW - AHSV KW - Himaeric virus-like particles KW - Orbivirus KW - Soluble viral protein 2 KW - VLPs KW - VP2 LK - https://researchspace.csir.co.za PY - 2022 SM - 0264-410X SM - 1873-2518 T1 - Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice TI - Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice UR - http://hdl.handle.net/10204/12545 ER - en_ZA
dc.identifier.worklist 26000 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record